- China
- /
- Life Sciences
- /
- SZSE:300759
Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Could Be 22% Below Their Intrinsic Value Estimate
Key Insights
- The projected fair value for Pharmaron Beijing is CN¥27.66 based on 2 Stage Free Cash Flow to Equity
- Pharmaron Beijing is estimated to be 22% undervalued based on current share price of CN¥21.55
- The CN¥22.97 analyst price target for 300759 is 17% less than our estimate of fair value
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Pharmaron Beijing Co., Ltd. (SZSE:300759) as an investment opportunity by taking the expected future cash flows and discounting them to today's value. The Discounted Cash Flow (DCF) model is the tool we will apply to do this. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine.
We would caution that there are many ways of valuing a company and, like the DCF, each technique has advantages and disadvantages in certain scenarios. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.
Check out our latest analysis for Pharmaron Beijing
Is Pharmaron Beijing Fairly Valued?
We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we need to discount the sum of these future cash flows to arrive at a present value estimate:
10-year free cash flow (FCF) estimate
2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | |
Levered FCF (CN¥, Millions) | CN¥1.69b | CN¥2.00b | CN¥2.23b | CN¥2.43b | CN¥2.60b | CN¥2.75b | CN¥2.89b | CN¥3.01b | CN¥3.13b | CN¥3.24b |
Growth Rate Estimate Source | Analyst x1 | Analyst x1 | Est @ 11.55% | Est @ 8.94% | Est @ 7.11% | Est @ 5.83% | Est @ 4.94% | Est @ 4.31% | Est @ 3.87% | Est @ 3.57% |
Present Value (CN¥, Millions) Discounted @ 7.8% | CN¥1.6k | CN¥1.7k | CN¥1.8k | CN¥1.8k | CN¥1.8k | CN¥1.8k | CN¥1.7k | CN¥1.7k | CN¥1.6k | CN¥1.5k |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = CN¥17b
We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.9%. We discount the terminal cash flows to today's value at a cost of equity of 7.8%.
Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = CN¥3.2b× (1 + 2.9%) ÷ (7.8%– 2.9%) = CN¥68b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= CN¥68b÷ ( 1 + 7.8%)10= CN¥32b
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is CN¥49b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Relative to the current share price of CN¥21.6, the company appears a touch undervalued at a 22% discount to where the stock price trades currently. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.
Important Assumptions
Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Pharmaron Beijing as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.8%, which is based on a levered beta of 0.984. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Pharmaron Beijing
- Earnings growth over the past year exceeded the industry.
- Debt is not viewed as a risk.
- Dividend is low compared to the top 25% of dividend payers in the Life Sciences market.
- Annual revenue is forecast to grow faster than the Chinese market.
- Good value based on P/E ratio and estimated fair value.
- Dividends are not covered by cash flow.
- Annual earnings are forecast to grow slower than the Chinese market.
Moving On:
Although the valuation of a company is important, it is only one of many factors that you need to assess for a company. The DCF model is not a perfect stock valuation tool. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. Why is the intrinsic value higher than the current share price? For Pharmaron Beijing, there are three pertinent aspects you should explore:
- Risks: For example, we've discovered 1 warning sign for Pharmaron Beijing that you should be aware of before investing here.
- Future Earnings: How does 300759's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!
PS. Simply Wall St updates its DCF calculation for every Chinese stock every day, so if you want to find the intrinsic value of any other stock just search here.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:300759
Pharmaron Beijing
Provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, and internationally.
Flawless balance sheet with solid track record.